/
We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on our proprietary arenavirus platform that is designed to target and amplify T cell and immune responses to fight diseases. Our replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.
$1.15
+$0.00 (+0.00%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-117.09% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 118.3% YoY with margins expanding 368.3pp.
Negative free cash flow of -$77M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$9M
▲ +118.3% YoY
Net Income (TTM)
-$73M
▲ +46.7% YoY
Op. Margin
-860.18%
▲ +368.3pp YoY
ROIC
-100.73%
▲ +20.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$53M
▼ -25.1% YoY
Op. Cash Flow (TTM)
-$53M
▼ -33.8% YoY
Net Debt
-$40M
Net Cash Position
Cash & Equiv.
$40M
5Y CAGR: +29.8%
Continue Research
Hookipa Pharma (HOOK)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Hookipa Pharma scores 20/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Hookipa Pharma scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -860.2% operating margin and a -100.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh HOOK's valuation and scores 20/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.